To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

NCT07098897 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

IgA Nephropathy (IgAN)

Interventions

DRUG: Telitacicept 160mg
DRUG: Corticosteroid
DRUG: ACE Inhibitor or Angiotensin receptor antagonist

Sponsor

The Affiliated Hospital of Xuzhou Medical University